TY - JOUR
T1 - Preprocedural anemia in females undergoing transcatheter aortic valve implantation
T2 - Insights from the WIN-TAVI registry
AU - Nicolas, Johny
AU - Claessen, Bimmer E.
AU - Cao, Davide
AU - Sartori, Samantha
AU - Baber, Usman
AU - Power, David
AU - Chiarito, Mauro
AU - Goel, Ridhima
AU - Roumeliotis, Anastasios
AU - Chandiramani, Rishi
AU - Chen, Siyan
AU - Chandrasekhar, Jaya
AU - Tchetche, Didier
AU - Petronio, Anna Sonia
AU - Mehilli, Julinda
AU - Lefèvre, Thierry
AU - Presbitero, Patrizia
AU - Capranzano, Piera
AU - Iadanza, Alessandro
AU - Sardella, Gennaro
AU - Van Mieghem, Nicolas M.
AU - Meliga, Emanuele
AU - Dumonteil, Nicolas
AU - Fraccaro, Chiara
AU - Trabattoni, Daniela
AU - Mikhail, Ghada
AU - Ferrer-Gracia, Maria Cruz
AU - Naber, Christoph
AU - Sharma, Samin
AU - Morice, Marie Claude
AU - Dangas, George D.
AU - Chieffo, Alaide
AU - Mehran, Roxana
N1 - Publisher Copyright: © 2020 Wiley Periodicals LLC.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Objectives: To assess the impact of anemia on clinical outcomes in female patients enrolled in the Women's InterNational transcatheter aortic valve implantation (WIN-TAVI) registry. Background: Anemia is highly prevalent among females who constitute half of TAVI candidates, yet, its clinical significance remains poorly investigated. Methods: Patients were divided into three groups according to preprocedural hemoglobin (Hb) level: (1) no anemia (Hb ≥12 g/dl), (2) mild-to-moderate anemia (10 ≤ Hb <12 g/dl), and (3) severe anemia (Hb <10 g/dl). The primary outcome was the occurrence of Valve Academic Research Consortium (VARC)-2 efficacy endpoint, a composite of mortality, stroke, myocardial infarction (MI), hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up. Results: Hemoglobin level was available in 877 (86.1%) patients: 412 (47.0%) had no anemia, 363 (41.4%) had mild-to-moderate anemia, and 102 (11.6%) had severe anemia. The latter group had a higher prevalence of cardiovascular risk factors. Compared with patients without anemia, severe anemia was associated with a greater risk of VARC-2 efficacy endpoint (adjHR 1.71, 95% CI: 1.02–2.87, p =.04), all-cause death (adjHR 2.36, 95% CI: 1.31–4.26, p =.004) and a composite of death, MI or stroke (adjHR 1.88, 95% CI: 1.10–3.22, p =.02) at 1 year. Moreover, an increased risk of late mortality (adjHR 1.15, 95% CI: 1.02–1.30, p =.03) was observed with every 1 g/dl decrease in hemoglobin level. Conclusion: Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.
AB - Objectives: To assess the impact of anemia on clinical outcomes in female patients enrolled in the Women's InterNational transcatheter aortic valve implantation (WIN-TAVI) registry. Background: Anemia is highly prevalent among females who constitute half of TAVI candidates, yet, its clinical significance remains poorly investigated. Methods: Patients were divided into three groups according to preprocedural hemoglobin (Hb) level: (1) no anemia (Hb ≥12 g/dl), (2) mild-to-moderate anemia (10 ≤ Hb <12 g/dl), and (3) severe anemia (Hb <10 g/dl). The primary outcome was the occurrence of Valve Academic Research Consortium (VARC)-2 efficacy endpoint, a composite of mortality, stroke, myocardial infarction (MI), hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up. Results: Hemoglobin level was available in 877 (86.1%) patients: 412 (47.0%) had no anemia, 363 (41.4%) had mild-to-moderate anemia, and 102 (11.6%) had severe anemia. The latter group had a higher prevalence of cardiovascular risk factors. Compared with patients without anemia, severe anemia was associated with a greater risk of VARC-2 efficacy endpoint (adjHR 1.71, 95% CI: 1.02–2.87, p =.04), all-cause death (adjHR 2.36, 95% CI: 1.31–4.26, p =.004) and a composite of death, MI or stroke (adjHR 1.88, 95% CI: 1.10–3.22, p =.02) at 1 year. Moreover, an increased risk of late mortality (adjHR 1.15, 95% CI: 1.02–1.30, p =.03) was observed with every 1 g/dl decrease in hemoglobin level. Conclusion: Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.
UR - http://www.scopus.com/inward/record.url?scp=85091773458&partnerID=8YFLogxK
U2 - 10.1002/ccd.29276
DO - 10.1002/ccd.29276
M3 - Article
C2 - 33002302
AN - SCOPUS:85091773458
SN - 1522-1946
VL - 97
SP - E704-E715
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 5
ER -